Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements for chemicals - a report by the Transatlantic Think Tank for Toxicology (t4) (original) (raw)
Authors
- Costanza Rovida Private Consultant, Varese, Italy
- Thomas Hartung Johns Hopkins University, Baltimore, USA; University of Konstanz, Germany
DOI:
https://doi.org/10.14573/altex.2009.3.187
Keywords:
REACH, chemicals, animal use, economics, statistics, policy
Abstract
The EU REACH legislation for chemicals of 2006 represents the largest investment into consumer product safety ever. A reanalysis of cost and animal use estimates was carried out based on the final legislation, test guidance for industry published by the European Chemical Agency, and the preregistration completed in December 2008. The new estimates for the number of substances falling under REACH range from 68 to 101,000 chemicals, substantially exceeding the earlier estimates of 29,000 substances. The latter estimates were, however, based on data before 1994 and both expansion of the EU and growth of the chemical industry since have contributed to higher numbers today.
The lower estimate of 68,000 chemicals was carried through current testing requirements with due regard to emerging alternative approaches, using in all cases the most optimistic assumptions (minimal animal numbers per test and neglecting most triggering of additional tests and confirmatory (re-)tests as well as tests requested but not yet defined for endocrine disruption, respiratory irritation, respiratory sensitization and developmental neurotoxicity). The most demanding studies are in the area of reproductive toxicity testing with about 90% of all animal use and 70% of the required costs for registration. The overall result suggests a demand of 54 million vertebrate animals and testing costs of 9.5 billion euro. This clearly challenges the feasibility of the program without a major investment into high-throughput methodologies.
License
Articles are distributed under the terms of the Creative Commons Attribution 4.0 International license (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium, provided the original work is appropriately cited (CC-BY). Copyright on any article in ALTEX is retained by the author(s).
How to Cite
“Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements for chemicals - a report by the Transatlantic Think Tank for Toxicology (t4)” (2009) ALTEX - Alternatives to Animal Experimentation, 26(3), pp. 187–208. doi:10.14573/altex.2009.3.187.
Most read articles by the same author(s)
- Lucy Meigs, Lena Smirnova, Costanza Rovida, Marcel Leist, Thomas Hartung, Animal testing and its alternatives – the most important omics is economics, ALTEX - Alternatives to Animal Experimentation: Vol. 35 No. 3 (2018)
- David Pamies, Marcel Leist, Sandra Coecke, Gerard Bowe, David G. Allen, Gerhard Gstraunthaler, Anna Bal-Price, Francesca Pistollato, Rob B. M. de Vries, Helena T. Hogberg, Thomas Hartung, Glyn Stacey, Guidance document on Good Cell and Tissue Culture Practice 2.0 (GCCP 2.0), ALTEX - Alternatives to Animal Experimentation: Vol. 39 No. 1 (2022)
- Thomas Hartung, Phasing in human-relevant science: Why the UK’s roadmap matters – and how to make it work, ALTEX - Alternatives to Animal Experimentation: Vol. 43 No. 1 (2026)
- Thomas Hartung, Nicole Kleinstreuer, Challenges and opportunities for validation of AI-based new approach methods, ALTEX - Alternatives to Animal Experimentation: Vol. 42 No. 1 (2025)
- Ronit Mohapatra, Marcel Leist, Sonja von Aulock, Thomas Hartung, Guidance for Good In Vitro Reporting Standards (GIVReSt) – A draft for stakeholder discussion and background documentation, ALTEX - Alternatives to Animal Experimentation: Vol. 42 No. 3 (2025)
- Thomas Hartung, Lena Smirnova, Stefan Platz, Ivano Amelio, Marcel Leist, The need for epigenotoxicity testing, ALTEX - Alternatives to Animal Experimentation: Vol. 42 No. 4 (2025)
- Uwe Marx, Takafumi Akabane, Tommy B. Andersson, Elizabeth Baker, Mario Beilmann, Sonja Beken, Susanne Brendler-Schwaab, Murat Cirit, Rhiannon David, Eva-Maria Dehne, Isabell Durieux, Lorna Ewart, Suzanne C. Fitzpatrick, Olivier Frey, Florian Fuchs, Linda G. Griffith, Geraldine A. Hamilton, Thomas Hartung, Julia Hoeng, Helena Hogberg, David J. Hughes, Donald E. Ingber, Anita Iskandar, Toshiyuki Kanamori, Hajime Kojima, Jochen Kuehnl, Marcel Leist, Bo Li, Peter Loskill, Donna L. Mendrick, Thomas Neumann, Giorgia Pallocca, Ivan Rusyn, Lena Smirnova, Thomas Steger-Hartmann, Danilo A. Tagle, Alexander Tonevitsky, Sergej Tsyb, Martin Trapecar, Bob van de Water, Janny van den Eijnden-van Raaij, Paul Vulto, Kengo Watanabe, Armin Wolf, Xiaobing Zhou, Adrian Roth, Biology-inspired microphysiological systems to advance patient benefit and animal welfare in drug development, ALTEX - Alternatives to Animal Experimentation: Vol. 37 No. 3 (2020)
- Jean Knight, Costanza Rovida, Reinhard Kreiling, Cathy Zhu, Mette Knudsen, Thomas Hartung, Continuing animal tests on cosmetic ingredients for REACH in the EU, ALTEX - Alternatives to Animal Experimentation: Vol. 38 No. 4 (2021)
- Lena Smirnova, Itzy E. Morales Pantoja, Thomas Hartung, Organoid intelligence (OI) – The ultimate functionality of a brain microphysiological system, ALTEX - Alternatives to Animal Experimentation: Vol. 40 No. 2 (2023)
- Uwe Marx, Sonja Beken, Zaozao Chen, Eva-Maria Dehne, Ann Doherty, Lorna Ewart, Suzanne C. Fitzpatrick, Linda G. Griffith, Zhongze Gu, Thomas Hartung, James Hickman, Donald E. Ingber, Seiichi Ishida, Jayoung Jeong, Marcel Leist, Lisa Levin, Donna L. Mendrick, Giorgia Pallocca, Stefan Platz, Marian Raschke, Lena Smirnova, Danilo A. Tagle, Martin Trapecar, Bas W. M. van Balkom, Janny van den Eijnden-van Raaij, Andries van der Meer, Adrian Roth, Biology-inspired dynamic microphysiological system approaches to revolutionize basic research, healthcare and animal welfare , ALTEX - Alternatives to Animal Experimentation: Vol. 42 No. 2 (2025)